Table 3.

Dose administration and dose reductions of omacetaxine [60]

Induction dosing	1.25 mg/m2 subcutaneously q12 h for 14 days over a 28-day cycle Cycles repeated until patient achieves a hematologic response
Maintenance dosing	1.25 mg/m2 subcutaneously q12 h for 7 days over a 28-day cycle Treatment continues as long as patients are receiving a clinical benefit
Dose delay/reduction	If grade 4 neutropenia (ANC < 0.5 × 109/L) or grade 3 thrombocytopenia (PLT < 50 × 109/L) occurs, delay the initiation of the next cycle until ANC ≥ 1.0 × 109/L and PLT ≥ 50 × 109/L For subsequent cycles, reduce the number of dosing days by 2 (to 12 or 5 days)
Monitoring	Induction cycles: weekly CBC First maintenance: weekly CBC Subsequent maintenance: fortnightly CBC

ANC absolute neutrophil count, PLT platelets, CBC complete blood count with differential